BCBS of Michigan made headlines by removing all GLP-1 weight loss medications including Zepbound, Wegovy, and Saxenda from fully insured large group commercial plans effective January 2025
While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked GLP-1 (glucagon-like peptide-1) agonists the class of drugs that includes semaglutides to an increased risk of hair loss
Mounjaro, on the other hand, requires refrigeration from the moment it is manufactured
A 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide had a higher observed risk of NAION compared with patients using non-GLP-1 medications for diabetes or weight loss
In recent years, several lawsuits have been filed against individuals and businesses marketing HCG for weight loss
It doesnt prescribe or supply medication